-
Thematic Analysis
NewSocial Media in Banking – Thematic Intelligence
Social Media in Banking Thematic Report Overview Social media companies will increasingly diversify away from their ad-funded business model in the face of increased regulatory scrutiny. Social media in banking thematic report maps out the prospects of social media giants for a deep assault on financial services, and how incumbent banks might respond. The report shares findings from GlobalData’s 2023 Financial Services Consumer Survey, which covers consumer openness to a wide variety of different types of financial services from different...
-
Thematic Analysis
NewSocial Media Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Gen Z favorite TikTok has grown very quickly over the last few years, reaching more than a billion users. However, there are signs that TikTok's growth has begun to plateau for the first time since its launch in 2016. It has also been caught in the US-China geopolitical tensions, with US lawmakers introducing legislation that would ban app stores from distributing TikTok unless ByteDance, its Chinese owner, divests control of the popular video-sharing platform. In the meantime, Instagram's push into...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Midomafetamine in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Midomafetamine in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Midomafetamine in Social Anxiety Disorder (SAD/Social Phobia) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYB-004 in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYB-004 in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYB-004 in Social Anxiety Disorder (SAD/Social Phobia) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNX-1900 in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNX-1900 in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNX-1900 in Social Anxiety Disorder (SAD/Social Phobia) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNC-210 in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNC-210 in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNC-210 in Social Anxiety Disorder (SAD/Social Phobia) Drug Details:...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Social Anxiety Disorder (SAD/Social Phobia) - Drugs In Development, 2023’, provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Thematic Analysis
ESG (Environmental, Social and Governance) Sentiment Polls Q4 2023 – Thematic Intelligence
ESG (Environmental, Social and Governance) Sentiment Polls Q4 2023 Thematic Report Overview Many companies are focusing on ESG performance plans to appeal to consumers and investors. In Q4 2023, there was an increase in employee awareness of company stances on ESG values compared to previous quarters in 2023. This is attributed to the rise in discussion of environmental and social issues and the COP28 event in December 2023. Many respondents believe that businesses still view ESG as just a marketing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALA-002 in Social Anxiety Disorder (SAD/Social Phobia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALA-002 in Social Anxiety Disorder (SAD/Social Phobia) Drug Details: ALA-002 is under investigation for the...